Antiviral Drugs Market Size & Share 2026-2035

Antiviral Drugs Market Size

The global antiviral drugs market was valued at USD 62 billion in 2025. The market is expected to grow from USD 63.6 billion in 2026 to USD 89.4 billion in 2035, at a CAGR of 3.9% during the forecast period, according to the latest report published by Global Market Insights Inc.

Antiviral medications are the pharmaceutical drugs that are used in the treatment of a viral infection by inhibiting the viral growth and replication. This essentially includes medication for HIV, AIDS, hepatitis and influenza. They assist in alleviating the symptoms and time frame of illness, and some also aid in preventing infection.
 

Moreover, the increase in awareness combined with government support and funding for easing the drug approvals, conducting clinical tests, and raising public awareness is anticipated to enhance the use of drugs in the market for antiviral treatments.
 

Key players in the antiviral drugs market include Gilead Sciences, GlaxoSmithKline, Merck, AbbVie, Johnson & Johnson, Bristol‑Myers Squibb, Novartis and Pfizer. These companies remain at the forefront of antiviral therapeutics through sustained R&D investment, development of next‑generation antivirals, expansion of portfolios targeting HIV, hepatitis, influenza, and emerging viral infections, and continued innovation in broad‑spectrum and combination therapies. Their strategic advancements supported by clinical pipeline expansion and global-scale manufacturing and distribution capabilities are instrumental in addressing the long‑term treatment and prevention needs associated with chronic and acute viral diseases worldwide.
 

Between 2022 and 2024, the antiviral drugs market experienced steady and sustained growth, by the persistent global burden of viral infections and continued demand for HIV, hepatitis, and influenza therapeutics. During this period, the global market expanded from approximately USD 58.5 billion in 2022 to USD 60.6 billion in 2024. Throughout 2024, the market-maintained stability as research and development efforts expanded, new mechanism‑based antivirals advanced, and access to antiviral therapies grew across both developed and emerging regions.  
 

Antiviral Drugs Market Trends

• Significant trends in the global antiviral drugs industry which include the burden of viral infection, development of novel antiviral drugs, and technology advancement in the drug development and increasing government spending in antiviral therapy adoption, support these therapies.
   
• As per the World Health Organization (WHO) report, nearly 39.9 million people were suffering from HIV by the end of 2023, out of which 1.4 million were children under fourteen years of age. This indicates that there is certainly a growing demand for effective treatment approaches.
   
• The growing prevalence of hepatitis is also pushing this market. Global Hepatitis Report 2024 by WHO, stated that Hepatitis is the second most infectious disease in the world for the number of yearly deaths, which is approximately 1.3 million people a year. Even with very effective treatment available, a large number of Hepatitis cases go undiagnosed. Therefore, an increasing trend of effective diagnostics and treatment regimens will augment the industry size.
   
• Similarly, in 2022, the Antiviral Drug Discovery Centers (AViDD) for Pandemic Pathogens was established by the NIAID in the U.S. These research facilities are highly focused on SARS-CoV-2 and various other viruses having pandemic potential such as bunyaviral, paramyxoviruses, togaviruses, picornaviruses and filoviruses, thereby leading to an increase in product launches in the future.
   
• Further, various governments as well as other private organizations have implemented awareness programs regarding the availability of advanced therapeutics for sexually transmitted diseases.
   
• Several key market players are actively involved in the development of novel drug therapeutics to treat infectious diseases that will strengthen the market growth potential.
   

Antiviral Drugs Market Analysis

Based on the drug class, the market is segmented into reverse transcriptase inhibitors, DNA polymerase inhibitors, protease inhibitors, neuraminidase inhibitors and other drug classes. The reverse transcriptase inhibitors segment accounted for 29.9% of market share and was valued at USD 18.6 billion in 2025.
 

• The growing rate of HIV/AIDS cases is a primary factor bringing in growth for the reverse transcriptase inhibitors segment, as these drugs are essential in the antiretroviral therapy for HIV treatment. Effectively treating diseases relies on the usage of reverse transcriptase inhibitors which include both nucleoside and non-nucleoside reverse transcriptase inhibitors (NRTIs & NNRTIs), respectively.
   
• Government spending for HIV treatment and awareness programs serve to increase popularity and usage of these drugs, creating growth for the segment.
   
• Also, reverse transcriptase inhibitors are widely used with several advantages offering such as higher success rate, affordability with low genetic barriers and enhanced bioavailability.
   
• Thus, with high potential to reduce the severity of HIV infections, expanding product availability, and novel product launches, the segment is expected to foresee significant product demand in the forthcoming years.
   
• Likewise, the DNA polymerase inhibitors segment is emerging as a steadily expanding category, which accounted for a CAGR of 4.3%, driven by rising prevalence of viral infections such as hepatitis and herpes, increasing clinical reliance on targeted antiviral mechanisms, and continued development of more precise, better‑tolerated polymerase‑blocking agents that strengthen treatment outcomes across diverse patient groups.
   

Based on the indication, the global antiviral drugs market is categorized into HIV/AIDS, hepatitis, coronavirus infection, herpes simplex virus (HSV), influenza, and other indications. The HIV/AIDS segment  is expected to reach USD 43.5 billion by 2035.
 

• The rising prevalence of HIV/AIDS infections is one factor primarily responsible for the expansion of the segment. In 2023, UNAIDS reports 1.3 million new cases of HIV, with 77% of HIV patients were on antiretroviral therapy drugs, highlighting the adoption rate of antiviral drugs used.
   
• Moreover, Antiretroviral Therapy (ART), which comes with different treatment options such as reverse transcriptase inhibitors (RTIs), protease inhibitors (PIs), and integrase strand transfer inhibitors (INSTIs), must be used long term to manage HIV/AIDS infection.
   
• Further, authorities such as the Food and Drug Administration (FDA) and European Medicines Agency are enhancing the development of this area, thereby fostering segmental growth over the coming years.
   
• On the other hand, the hepatitis segment is poised for sustained growth, stimulated by the high global burden of chronic HBV and HCV infections and the strong clinical performance of advanced antiviral therapies that continue to enhance treatment efficacy and long‑term disease management outcomes.
   

Based on type, the global antiviral drugs market is classified into branded and generic. The branded segment held market share of 71.8% in 2025.
 

• The branded drugs undergo rigorous research and clinical trials that ensure safety and efficacy of the antiviral drugs. These drugs offers better outcomes compared to generic drugs, thus making them benefitial for treating chronic viral infections requiring long-term treatment.
   
• Further as the pharmaceutical companies significantly invest on enhancing the availability and accessibility of these drugs, there is an increased demand and adoption of branded drugs. For instance, Aurobindo Pharma’s product Molnaflu, for COVID-19 treatment, strengthened the company’s product portfolio thereby, creating revenue growth opportunities.
   
• Therefore, owing to the proven safety and efficacy of branded drugs along with avialability of several drugs in the market, there will be increase brand adoption.
   
• In contrast, the generic antiviral drugs segment is driven by the growing introduction of lower‑cost generic versions of established antivirals and increasing global awareness of accessible treatment options that support patient adoption and market growth.
   

Based on route of administration, the global antiviral drugs market is bifurcated into oral, parenteral, topical and other routes of administration. The oral segment dominated the market in 2025 and is poised to witness growth at 3.8% CAGR over the analysis period.
 

• Oral segment dominated the market due to the advantages it offers compared to parenteral route of administration, including ease of administration and non-invasiveness. This increased adherence to the treatment make oral route as preferred choice for treating chronic diseases which requires long-term treatment.
   
• The ongoing advances in oral drug formulations such as once-weekly oral regimen for HIV treatment is expected to contribute to the growth of this segment. For instance, Conference on Retroviruses and Opportunistic Infections (CROI 2024) presented a phase II trial of 94% of individuals shifted to weekly islatravir and lenacapavir pills maintained viral suppression rate like those who took Biktarvy daily.
   
• This gradual shift of treatment regimen is expected to improve treatment adherence, convenience and treatment outcomes, thereby contributing to the growth of this segment.
   
• Likewise, the parenteral antiviral drugs segment is stimulated by its critical role in managing severe viral infections, where injectable therapies including hospital‑administered antivirals ensure rapid systemic action.
   

Based on age group, the global antiviral drugs market is divided into geriatric, adult and pediatric. In 2025, the geriatric segment was valued at USD 27.5 billion and is expected to reach USD 39.3 billion by end of 2035.
 

• The growth of this segment is majorly contributed to the rapidly growing aging population. For instance, as per WHO, 1 in 6 individuals globally will be aged 60 years and older by 2030, therefore stimulating the market demand for antivirals.
   
• Similarly, by 2050 the population of the 60 year and older age group is expected to reach 2.1 billion. This increasing demographic indicates the demand for effective treatment as they are more likely to get infected with viral infections.
   
• Further, another significant factor stimulating the growth is the widespread adoption of antiviral drugs and vaccines for influenza and respiratory syncytial virus (RSV) cases common among this age group.
   
• On the other hand, the adult segment is stimulated by the high global incidence of viral infections such as HIV and hepatitis in the adult population, alongside strong treatment demand supported by wide clinical adoption and expanding access to effective antiviral therapies.

Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies segment in 2025 held the highest market share of 46.6%.
 

• Hospitals are the epicenter or primary treatment centers for viral infections such as hepatitis, HIV/AIDS and influenza where patients receive immediate access to antiviral drugs.
   
• Also, the complexity of severe viral infections requires hospitalization, thus the increase in patient pool visiting hospitals will spur the growth of hospital pharmacies in the global antiviral drugs market. The availability of a wide range of antiviral drugs with different formulations further solidifies the dominance of hospital pharmacies.
   
• Moreover, incidence of newly emerging infectious diseases with no prior approved medications leads to high usage of recently launched branded drugs that will fortify the overall market outlook during the projection period.
   
• The online pharmacies segment is gaining momentum, escalating by rising digital adoption, increased patient preference for convenient access to antiviral medications, and broader availability of therapies through e‑commerce platforms that enhance treatment reach and affordability.

North America Antiviral Drugs Market

The North America region dominated with a 40.1% share of antiviral drugs industry in 2025.
 

• North America leads the global market, stimulated by advanced healthcare infrastructure, high research and development expenditure, and strong uptake of innovative antiviral therapies.
   
• The region benefits from early adoption of next‑generation therapeutics and diagnostic technologies, supported by major industry players who drive innovation through robust pipelines, strategic acquisitions, and accelerated development of breakthrough antiviral treatments.
   

The U.S. antiviral drugs market was valued at USD 21.5 billion and USD 21.9 billion in 2022 and 2023, respectively. The market size reached USD 22.7 billion in 2025, growing from USD 22.2 billion in 2024.
 

• This market is expanding owing to increasing governmental initiatives and rising viral infections across the country. For example, the Viral Hepatitis Plan is designed to eliminate viral hepatitis as a public health issue in the U.S. by 2030. This plan targets hepatitis A, B, and C.
   
• Similarly, the ending of the HIV epidemic (EHE) initiative that targets 57 priority jurisdictions and intensifying diagnose, treat, prevent, and respond activities has also contributed to the market growth.
   
• EHE's aimed to reduce new HIV infections in the U.S. by 90% by 2030 with advancing health equity by scaling up key HIV prevention and treatment strategies. These initiatives help increase the use of antiviral drugs in the treatment of viral infections.
   

Europe Antiviral Drugs Market

Europe market accounted for USD 18.1 billion in 2025 and is anticipated to show lucrative growth over the forecast period.
 

• Europe maintains strong momentum in the antiviral drugs industry, supported by high disease prevalence including widespread cases of HIV, hepatitis, influenza and other viral infections and strong adoption of clinically validated antiviral therapies.
   
• Also, the strong presence of pharmaceutical companies and research institutes enables the development and distribution of novel antiviral medications such as long-acting and direct-acting antivirals.
   

Germany dominates the Europe antiviral drugs market, with strong growth potential.
 

• The high HIV cases in Germany is stimulating the market demand. As mentioned by Robert Koch Institute, in Germany there were more than 90,000 people living with HIV, and roughly 2,200 new infections are recorded. This highlights the need for proactive screening and efficacious antiretroviral therapy, which increases the need for advanced antiviral drugs.
   
• Also, market penetration is further strengthened by rapid adoption of innovative antiviral modalities, supported by rising prevalence of chronic viral diseases and increasing integration of precision‑medicine across German healthcare settings.
   

Asia Pacific Antiviral Drugs Market

The Asia Pacific market is anticipated to grow at the highest CAGR of 4.2% during the analysis timeframe.
 

• The region experiences public health investments and strengthens government‑led vaccination and treatment programs across APAC are stimulating antiviral adoption as countries scale up early diagnosis, treatment access, and disease‑control initiatives.
   
• Moreover, factors, such as population density, international travel, and seasonal variations are contributing to the widespread transmission of viruses, leading to a high demand for influenza medication.
   
• Also, the increasing pharmaceutical industry also drives the growth of the region in antiviral drugs industry. Players such as Cipla, Dr. Reddy's Laboratories, Sun Pharma, and Mylan enhance the availability and affordability of both branded and generic medications in the market.
   

China antiviral drugs market is estimated to grow with a significant CAGR, in the Asia Pacific market.
 

• The high chronic hepatitis B prevalence and persistent adult‑population treatment need drive substantial antiviral therapy consumption, with China accounting for a major share of more than 87 million hepatitis B cases in the country as mentioned by WHO.
   
• Also, strengthening of national infectious‑disease control programs, expanded hospital infrastructure, and increased government emphasis on treatment accessibility are boosting uptake of direct‑acting antivirals and combination therapies.
   

Latin American Antiviral Drugs Market

Brazil leads the Latin American antiviral drugs industry, exhibiting remarkable growth during the analysis period.
 

• The growing adoption of combination therapies and next‑generation antiviral formulations including nucleoside analogues and protease inhibitors is improving treatment outcomes and reducing resistance, further driving therapeutic uptake across Brazil.
   
• Also, regulatory support and rapid approval pathways for emergency use antiviral treatments, combined with expanding research and development investments, are stimulating availability of innovative therapies and strengthening Brazil’s pharmaceutical ecosystem.
   

Middle East and Africa Antiviral Drugs Market

Saudi Arabia market for antiviral drugs is expected to experience substantial growth in the Middle East and Africa .
 

• Saudi Arabia is experiencing an increased rate of viral and respiratory infections which are the means to the growing usage of antiviral drugs. The country is stepping up in the control of infectious diseases through improvement in medical research, pharmaceutical production, and the broader accessibility of healthcare by means of tools such as the Saudi Vision 2030 healthcare transformation plan.
   
• Thus, proactive collaborations and strategic efforts by market players to broaden their manufacturing capacities antiviral drugs for catering to a large patient base have fueled the overall antiviral drugs market share.
   

Antiviral Drugs Market Share

The global market is defined by a concentrated yet highly competitive environment, with a select group of leading pharmaceutical companies Gilead Sciences, GlaxoSmithKline, Merck & Co., F. Hoffmann‑La Roche and AbbVie collectively accounting for approximately 30% of global revenues. Their dominance is anchored in extensive antiviral portfolios, long‑standing leadership in HIV, hepatitis and influenza therapies, and deep research pipelines that continue to shape global treatment standards.
 

These companies maintain competitive advantage through broad product lines, advanced development platforms, strong commercial capabilities, and global distribution reach, enabling them to serve large and diverse patient populations across both developed and emerging markets. Gilead Sciences leads with transformative HIV and hepatitis therapies; GSK continues to advance long‑acting antivirals; Merck builds market presence through COVID‑19 antivirals and emerging influenza biologics; Roche integrates antiviral therapeutics with diagnostics for enhanced clinical accuracy; and AbbVie remains prominent in the hepatitis C segment. Strategic expansion through licensing agreements, global partnerships, acquisition‑driven pipeline strengthening, and investments in high‑value biologics continues to define competitive dynamics.
 

Industry leaders are actively investing in next‑generation antiviral platforms, including long‑acting agents, combination regimens, precision‑targeted polymerase and protease inhibitors, and advanced biologics, in response to a rising global prevalence of chronic and acute viral infections. Innovation priorities also include personalized medicine, improved delivery systems, and expanded R&D in emerging viral threats, underscoring the continued global need for broad‑spectrum, resistance‑mitigating antiviral therapies.
 

Antiviral Drugs Market Companies

Few of the prominent players operating in the antiviral drugs industry include:

• AbbVie
• AstraZeneca
• Aurobindo Pharma
• Bristol-Myers Squibb
• Cipla
• Dr. Reddy's Laboratories
• F. Hoffmann-La Roche
• Gilead Sciences
• GlaxoSmithKline
• Johnson & Johnson
• Merck
• Novartis
• Pfizer
• Sun Pharmaceutical
• Takeda Pharmaceutical
• Viatris
   
• Gilead Sciences

Gilead Sciences holds a leading position in the global antiviral drugs market, strengthened by its dominant portfolio across HIV, hepatitis B and C, and COVID‑19 therapies, supported by decades of innovation in virology and high‑impact product launches such as Biktarvy and remdesivir. The company’s sustained leadership is reinforced by its robust R&D engine, expanding pipeline of long‑acting antivirals, and strategic global partnerships that broaden treatment access and strengthen its influence across major therapeutic categories.
 

• GlaxoSmithKline

GlaxoSmithKline maintains a strong competitive standing through its extensive antiviral capabilities, driven by ViiV Healthcare’s leadership in HIV treatment and its active development of long‑acting antiviral formulations. GSK continues to expand its impact through strategic R&D advancements, vaccine‑adjacent antiviral innovation, and strengthened regional presence across APAC and Europe, supported by partnerships that enhance therapy availability and accelerate adoption of next‑generation antiviral solutions.
 

• Merck

Merck maintains a solid competitive foothold in the antiviral landscape, powered by its diversified antiviral portfolio including molnupiravir and a promising late‑stage universal influenza antiviral candidate, CD388. Continued investment in cutting‑edge antiviral platforms, strengthened by targeted acquisitions and global expansion initiatives, supports Merck’s long‑term growth strategy as it advances innovative therapeutic solutions addressing both chronic and emerging viral threats.
 

Antiviral Drugs Industry News

• In December 2025, Decoy Therapeutics partnered with the Texas Biomedical Research Institute to conduct in‑vitro studies of its peptide‑conjugate influenza fusion inhibitors across multiple seasonal and avian flu strains. This enhanced Salarius early‑stage antiviral pipeline credibility and validated its multi‑virus therapeutic platform.
   
• In November 2025, Merck completed an acquisition of Cidara Therapeutics, securing CD388, a late‑stage antiviral candidate designed to provide long‑acting prevention against influenza. This strengthened Merck’s antiviral pipeline with a potential blockbuster flu‑prevention asset.
   
• In April 2023, Shionogi announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its investigational oral antiviral ensitrelvir for COVID-19 treatment. This has improved the company’s competitive edge, strengthening its presence in antiviral drugs market.
   
• In December 2021, Cipla Limited announced that it has received Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) to launch Molnupiravir in India. This approval helped the company to strengthen its position in the market and boost revenue and market credibility.
   

The antiviral drugs market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Class

• Reverse transcriptase inhibitors
• DNA polymerase inhibitors
• Protease inhibitors
• Neuraminidase inhibitors
• Other drug classes

Market, By Indication

• HIV/AIDS
• Hepatitis
• Coronavirus infection
• Herpes simplex virus (HSV)
• Influenza
• Other indications

Market, By Type

• Branded
• Generic

Market, By Route of Administration

• Oral
• Parenteral
• Topical
• Other routes of administration

Market, By Age Group

• Geriatric
• Adult
• Pediatric

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea

• Latin America
  • Brazil
  • Mexico
  • Argentina

• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE